MMP9 and endometrioid adenocarcinoma: A significantly higher percentage of slides expressed MMP-9 with a low immunoreactivity in grade 1 (90%) but not in grade 2 (71.4%) (Figure 1F) and grade 3 (66.7%) endometrioid carcinoma when compared with atrophic endometrium (20%) (p < 0.05).